Antisense oligonucleotide therapeutics

Bibliography

• HELENE C, TOULME J-J: Specific regulation of gene ex-pression by antisense, sense and antigene nucleic ac-ids. Biochim. Biophys. Acta. (1990) 1049:99–125.
   PubMed Web of Science ®Google Scholar
• BENNETT CF, CROOKE ST: Regulation of endothelial cell adhesion molecule expression with antisense oli-gonucleotides. Adv. Pharmacol. (1994) 28:1–43.
   PubMedGoogle Scholar
• CROOKE ST: Therapeutic Applications of Oligonucleo-tides. RG Landes Company, Austin (1995):138.
   Google Scholar
• CROOKE ST, BENNETT CF: Progress in antisense oligo-nucleotide therapeutics. Ann. Rev. Pharmacol Toxicol. (1996) 36:107–129.
   PubMed Web of Science ®Google Scholar
• CROOKE ST: Therapeutic applications of oligonucleo-tides. Ann. Rev. Pharmacol. Toxicol. (1992) 32:329–376.
   PubMed Web of Science ®Google Scholar
• YACYSHYN BR, BOWEN-YACYSHYN MB, JEWELL L et al: A placebo-controlled trial of ICAM-1 antisense oligo-nucleotide in the treatment of Crohn's disease. Gastro-enterology (1998) 114:1133–1142.
   PubMed Web of Science ®Google Scholar
• GLOVER JM, LEEDS JM, MANT TGK et al.: Phase I safety and pharmacokinetic profile of an ICAM-1 antisense oligodeoxynucleotide (ISIS 2302). J. Pharmacol Exp. Ther. (1997) 282:1173–11980.
   PubMed Web of Science ®Google Scholar
• BISHOP MR, IVERSEN PL, BAYEVER E et al: Phase! trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J. Gun. Oncol. (1996) 14:1320–1326.
   Web of Science ®Google Scholar
• WEBB A, CUNNINGHAM D, COTTER F et al:. BCL-2 an-tisense therapy in patients with non-Hodgkin's lym-phoma. Lancet (1997) 349:1137–1141.
   PubMed Web of Science ®Google Scholar
• STEIN CA, KRIEG AM: Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res. Dev. (1994) 4:67–69.
   PubMedGoogle Scholar
• STEIN CA, CHENG Y-C: Antisense oligonucleotides as therapeutic agents-is the bullet really magical? Science (1993) 261:1004–1012.
   PubMed Web of Science ®Google Scholar
• WAGNER RW: Gene inhibition using antisense oligode-oxynucleotides. Nature (1994) 372:333–335.
   PubMed Web of Science ®Google Scholar
• BRANCH AD: A hitchhiker's guide to antisense and nonantisense biochemical pathways. Hepatol. (1996) 24:1517–1529.
   PubMed Web of Science ®Google Scholar
• BENNETT CF: Antisense oligonucleotides: is the glasshalf full or half empty? Biochem. Pharmacol. (1997) 55:9–19.
   Web of Science ®Google Scholar
• CHIANG M-Y, CHAN H, ZOUNES MA, FREIER SM, LIMAWF, BENNETT CF: Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J. Biol. Chem. (1991) 266:18162–18171 .
   PubMed Web of Science ®Google Scholar
• MONIA BP, JOHNSTON JF, ECKER DJ, ZOUNES M, LIMA WF, FREIER SM: Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. J. Biol. Chem. (1992) 267:19954–19962.
   PubMed Web of Science ®Google Scholar
• MONIA BP, LESNIK EA, GONZALEZ C et al: Evaluation of 2' modified oligonucleotides containing deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. (1993) 268:14514–14522.
   PubMed Web of Science ®Google Scholar
• SHARMA HW, NARAYANAN R: The therapeutic potential of antisense oligonucleotides. BioEssays (1995) 17:1055–1063.
   PubMed Web of Science ®Google Scholar
• DEAN NM, MCKAY R, MIRAGLIA L et al: Antisense oligo-nucleotides as inhibitors of signal transduction: devel-opment from research tools to therapeutic agents. Biochem. Soc. Trans. (1996) 24:623–629.
   PubMed Web of Science ®Google Scholar
• HOKE GD, DRAPER K, FREIER SM et al.: Effects of phos-phorothioate capping on antisense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection. Nucleic Acids Res. (1991) 19:5743–5748.
   PubMed Web of Science ®Google Scholar
• SHAW J-P, KENT K, BIRD J, FISHBACK J, FROEHLER B:Modified deoxyoligonucleotides stable to exonuclease degradation in serum. Nucleic Acids Res. (1991) 19:747–750.
   PubMed Web of Science ®Google Scholar
• MATTEUCCI M: Structural modifications toward im-proved antisense oligonucleotides. Perspectives Drug Dis. Des. (1996) 4:1–16.
   Web of Science ®Google Scholar
• MILLIGAN JF, MATTEUCCI MD, MARTIN JC: Current con-cepts in antisense drug design. J. Med. Chem. (1993) 36:1923–1937.
   PubMed Web of Science ®Google Scholar
• GRIFFEY RH, MONIA BP, CUMMINS LL et al.: 2'4)--aminopropyl ribonucleotides: a zwitterionic modifi-cation that enhances the exonuclease resistance and biological activity of antisense oligonucleotides. Med. Chem. (1996) 39:5100–5109.
   Web of Science ®Google Scholar
• ALTMANN K-H, DEAN NM, FABBRO D et al.: Second gen-eration of antisense oligonucleotides: from nuclease resistance to biological efficacy in animals. Chimia. (1996) 50:168–176.
   Web of Science ®Google Scholar
• SANGHVI YS, COOK PD: Carbohydrate Modifications In Antisense Research American Chemical Society Sympo-sium Series No. 580. Washington, DC, USA (1994). Abstract 232.
   Google Scholar
• CROOKE ST, GRAHAM MJ, ZUCKERMAN JE et al: Pharma-cokinetic properties of several novel oligonucleotide analogs in mice. J. Pharmacol Exp. Ther. (1996) 277:923–937.
   PubMed Web of Science ®Google Scholar
• MCKAY RM, CUMMINS LL, GRAHAM MJ et al.: Enhanced activity of an antisense oligonucleotide targeting murine PKC-a by the incorporation of 2'-0-propyl modifications. Nuc. Acid Res. (1996) 24:411–417.
   PubMed Web of Science ®Google Scholar
• MONIA B, JOHNSTON JF, SASMOR H, CUMMINS LL: Nucle-ase resistance and antisense activity of modified oligo-nucleotides targeted to ha-ras. J. Biol. Chem. (1996) 24:14533–14540.
   Google Scholar
• DE CLERCQ E, ECKSTEIN F, MERIGAN TC: Iterferon in-duction increased through chemical modification of synthetic polyribonucleotide. Science (1969) 165:1137–1140.
   PubMed Web of Science ®Google Scholar
• STEIN CA: Does antisense exist? Nature Med. (1995) 1:1119–1121.
   Google Scholar
• STEIN CA: Phosphorothioate antisense oligodeoxynu-cleotides: questions of specificity. TIBTECH (1996) 14:147–149.
   PubMed Web of Science ®Google Scholar
• AGRAWAL S, TEMSAMANI J, TANG JY: Pharmacokinet-ics, biodistribution, and stability of oligodeoxynucleo-tide phosphorothioates in mice. Proc. Natl. Acad. Sci. USA (1991) 88:7595–7599.
   PubMed Web of Science ®Google Scholar
• AGRAWAL S, TEMSAMANI J, GALBRAITH W, TANG J: Pharmacokinetics of antisense oligonucleotides. Clin. Pharmacokinet. (1995) 28:7–16.
   PubMed Web of Science ®Google Scholar
• ZHANG R, YAN J, SHAHINIAN H et al.: Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin. Pharmacol. Ther. (1995) 58:44–53.
   PubMed Web of Science ®Google Scholar
• COSSUM PA, SASMOR H, DELLINGER D et al: Dispositionof the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J. Pharmacol. Exper. Ther. (1993) 267:1181–1190.
   PubMed Web of Science ®Google Scholar
• GEARY RS, LEEDS JM, FITCHETT J et al: Pharmacokinet-ics and metabolism in mice of a phosphorothioate oli-gonucleotide antisense inhibitor of C-raf-1 kinase expression. Drug Metab. Disp. (1997) 25:1272–1281.
   PubMed Web of Science ®Google Scholar
• GEARY RS, LEEDS J, HENRY SP, MONTEITH DK, LEVIN AA:Antisense oligonucleotide inhibitors for the treatment of cancer: 1) pharmacokinetic properties of phos-phorothioate oligodeoxynucleotides. Anticancer Drug Des. (1997) 12:383–393.
   PubMedGoogle Scholar
• SANDS H, GOREY-FERET LJ, COCUZZA AJ, HOBBS FW,CHIDESTER D, TRAINOR GL: Biodistribution and me-tabolism of internally 311-labeled oligonucleotides. I. Comparison of a phosphodiester and a phos-phorothioate. Mol Pharmacol. (1994) 45:932–943.
   PubMed Web of Science ®Google Scholar
• KUMAR S, TEWARY HK, IVERSEN PL: Characterization ofbinding sites, extent of binding, and drug interactions of oligonucleotides with albumin. Antisense Res. Dev. (1995) 5:131–139.
   PubMedGoogle Scholar
• QIAN M, CHEN S-H, VON HOFE E, GALLO JM: Pharma-cokinetics and tissue distribution of a DNA-methyltransferase antisense (MT-AS) oligonucleotide and its catabolites in tumor bearing nude mice. J. Phar-macol. Exp. Therap. (1997) 282:663–670.
   PubMed Web of Science ®Google Scholar
• LEVIN AA, MONTEITH DK, LEEDS JM et al: Toxicity of oli-godeoxynucleotide therapeutic agents. In: Antisense Re-search and Applications. Crooke ST (Ed.) Springer-Verlag, Heidelberg (In Press).
   Google Scholar
• COSSUM PA, TRUONG L, OWENS SR, MARKHAM PM, SHEA JP, CROOKE ST: Pharmacokinetics of a 14C -l-abelled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats. J. Pharmacol Exp. Ther. (1994) 269:89–94.
   PubMed Web of Science ®Google Scholar
• AGRAWAL S, ZHANG X, LU Z et al.: Absorption, tissuedistribution and in vivo stability in rats of a hybrid an-tisense oligonucleotide following oral administration. Biochem. Pharmacol. (1995) 50:571–576.
   PubMed Web of Science ®Google Scholar
• PLENAT F, KLEIN-MONHOVEN N, MARIE B, VIGNAUD J-M, DUPREZ A: Cell and tissue distribution of synthetic oligonucleotides in healthy and tumor-bearing nude mice. Am. J. Pathol. (1995) 147:124–135.
   PubMed Web of Science ®Google Scholar
• RAPPAPORT J, HANSS B, KOPP JB et al.: Transport ofphosphorothioate oligonucleotides in kidney: impli-cations for molecular therapy. Kidney Int. (1995) 47:1462–1469.
   PubMed Web of Science ®Google Scholar
• BUTLER M, STECKER K, BENNETT CF: Cellular distribu-tion of phosphorothioate oligodeoxynucleotides in normal rodent tissues. Lab. Invest. (1997) 77: 379–388.
   PubMed Web of Science ®Google Scholar
• BIJSTERBOSCH MK, MANOHARAN M, RUMP ET et al: Invivo fate of phosphorothioate antisense oligode-oxynucleotides: predominant uptake by scavenger re-ceptors on endothelial cells. Nucleic Acids Res. (1997) 25:3290–3296.
   PubMed Web of Science ®Google Scholar
• GRAHAM MJ, CROOKE ST, MONTEITH DK et al In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous ad-ministration. J. Pharmacol. Exp. Ther. (1998) 286:447–458.
   PubMed Web of Science ®Google Scholar
• SAWAI K, TAKENORI M, TAKAKURA Y, HASHIDA M: Re-nal disposition characteristics of oligonucleotides modified at terminal linkages in perfused rat kidney. Antisense Res. Dev. (1995) 5:279–287.
   PubMedGoogle Scholar
• KOZIOLKIEWICZ M, WOJCIK M, KOBYLANSKA A et al.:Stability of stereoregular oligo (nucleoside phos-phorothioate)s in human plasma: Diastereoselectivity of plasma 3,-.-exonuclease. Antisense Nucleic Add Drug Dev. (1997) 7:43–48.
   Google Scholar
• MONTEITH DK, HENRY SP, HOWARD RB et al: Immunestimulation-A class effect of phosphorothioate oligo-nucleotides in rodents. Anticancer Drug Des. (1997) 12:421–432.
   PubMedGoogle Scholar
• HENRY SP, TAYLOR J, MIDGLEY L, LEVIN AA, KORN-BRUST DJ: Evaluation of the toxicity profile of ISIS 2302, a phosphorothioate oligonucleotide, following repeated intravenous administration: 1) 4-week study in CD-1 mice. Antisense Nucleic Acid Drug Dev. (1997) 7:473–481.
   PubMedGoogle Scholar
• KRIEG A, GAUSE WC, GOURLEY MF, STEINBERG AD: Arole for endogenous retroviral sequences in the regu-lation of lymphocyte activation. J. Immunol. (1989) 143:2448–2451.
   PubMed Web of Science ®Google Scholar
• BRANDA RF, MOORE AL, MATHEWS L, MCCORMACK JJ,ZON G: Immune stimulation by an antisense oligomer complementary to the rev gene of 11IV-1. Biochem. Pharmacol. (1993) 45:2037–2043.
   PubMed Web of Science ®Google Scholar
• PISETSKY DS, REICH C: Stimulation of in vitro prolifera-tion of murine lymphocytes by synthetic oligode-oxynucleotides. Mol. Biol. Rep. (1993) 18:217–221.
   PubMed Web of Science ®Google Scholar
• PISETSKY DS, REICH CF: Stimulation of murine lympho-cyte proliferation by a phosphorothioate oligonucleo-tide with antisense activity for herpes simplex virus. Life Sci. (1994) 54:101–107.
   PubMed Web of Science ®Google Scholar
• LIANG H, NISHIOKA Y, REICH CF, PISETSKY DS, LIPSKYPE: Activation of human B cells by phosphorothioate oligodeoxynucleotides. j Clin. Invest. (1996) 98:1119–1129.
   PubMed Web of Science ®Google Scholar
• KRIEG AM, YI A-K, MATSON S et al.: CpG motifs in bacte-rial DNA trigger direct B-cell activation. Nature (1995) 374:546–549.
   PubMed Web of Science ®Google Scholar
• BENNETT CF, KORNBRUST D, HENRY S et al.: An ICAM-1antisense oligonucleotide prevents and reverses dex-tran sulfate sodium-induced colitis in mice. J. Pharma-col. Exp. Ther. (1997) 280:988–1000.
   PubMed Web of Science ®Google Scholar
• DEAN NM, MCKAY R, MIRAGLIA L et al.: Inhibition ofgrowth of human tumor cell lines in nude mice by an antisense oligonucleotide inhibitor of PKC-a F255 ex-pression. Cancer Res. (1996) 56:3499–3507.
   PubMed Web of Science ®Google Scholar
• STACEY KJ, SWEET MJ, HUME DA: Macrophages ingestand are activated by bacterial DNA. J. Immunol. (1996) 157:2116–2122.
   PubMed Web of Science ®Google Scholar
• KURAMOTO E, YANO 0, KIMURA Y et al.: Oligonucleo-tide sequences required for natural killer cell activa-tion. Jpn. J. Cancer Res. (1992) 83:1128–1131.
   Google Scholar
• BALLAS ZK, RASMUSSEN WL, KRIEG AM: Induction of NKactivity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J. Immunol. (1996) 157:1840–1845.
   PubMed Web of Science ®Google Scholar
• BENIMETSKAYA L, LOIKE JD, KHALED Z et al.: Mac-1(CD11b/CD18) is an oligodeoxynucleotide-binding protein. Nature Med. (1997) 3:414–420.
   PubMed Web of Science ®Google Scholar
• BOGGS RT, MCGRAW K, CONDON T et al.: Characteriza-tion and modulation of immune stimulation by modi-fied oligonucleotides. Antisense Nucleic Add Drug Dev. (1997) 7:461–471.
   PubMedGoogle Scholar
• YI A-Y, HORNBECK P, LAFRENZ DE, KRIEG AM: CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of c-myc and bc1-X1. j Immunol. (1996) 157:4918–4925.
   PubMed Web of Science ®Google Scholar
• YI AK, KLINMAN DM, MARTIN TL, MATSON S, KRIEG AM:Rapid immune activation by CpG motifs in bacteria DNA: systemic induction of IL-6 transcription through antioxidant-sensitive pathway. J. Immunol. (1996) 157:5394–5402.
   PubMed Web of Science ®Google Scholar
• GALBRAITH WM, HOBSON WC, GICLAS PC, SCHECHTERPJ, AGRAWAL S: Complement activation and hemody-namic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res. Dev. (1994) 4:201–206.
   PubMedGoogle Scholar
• CORNISH KG, IVERSEN P, SMITH L, ARNESON M, BAYEVER E: Cardiovascular effects of a phos-phorothioate oligonucleotide to p53 in the conscious rhesus monkey. Pharmacol Comm. (1993) 3:239–247.
   Google Scholar
• HENRY SR, GICLAS PC, LEEDS J et al.: Activation of the al-ternative pathway of complement by a phos-phorothioate oligonucleotide: potential mechanism of action. J. Pharmacol. Exp. Ther. (1997) 281:810–816.
   PubMed Web of Science ®Google Scholar
• COOK D: Antisense medicinal chemistry. In: Antisense Research and Application. Crooke ST (Ed.), Springer, Berlin, Germany (1998):51–102.
   Google Scholar
• INOUE H, HAYASE Y, IMURA A et al.: Synthesis and hy-bridization studies on two complementary nona(2'-0-methyl) ribonucleotides . Nucleic Acids Res. (1987) 15:6131–6148.
   PubMed Web of Science ®Google Scholar
• IRIBARREN AM, SPROAT BS, NEUNER P et al.: 2'-0-alkyl oligoribonucleotides as antisense probes. Proc. Natl. Acad. Sci. USA (1990) 87:7747–7751.
   PubMed Web of Science ®Google Scholar
• FREIER SM, ALTMANN KH: The ups and downs of nu-cleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes. Nucleic Acids Res. (1997) 25:4429–43.
   PubMed Web of Science ®Google Scholar
• BAKER BF, LOT SF, CONDON TP et al.: 2'4)42-methoxylethyl modified anti-ICAM-1 oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation intiation complex in HUVECs. J. Biol. Chem. (1997) 272:11994–12000.
   PubMed Web of Science ®Google Scholar
• LAMOND Al, SPROAT BS: Antisense oligonucleotidesmade of 2'-0-alky1RNA: their properties and applica-tions in RNA biochemistry. FEBS Lett. (1993) 325:123–127.
   PubMed Web of Science ®Google Scholar
• ZHANG R, LU Z, ZHAO H et al.: In vivo stability, disposi-tion and metabolism of a 'hybrid' oligonucleotide phosphorothioate in rats. Biochem. Pharmacol. (1995) 50:545–556.
   PubMed Web of Science ®Google Scholar
• MCKAY R, MIRAGLIA L, CUMMINS L et al: Characteriza-tion of a potent and specific class of antisense oligonu-cleotide inhibitors of human PKC-alpha expression. J. Biol. Chem. (1999) 274:1715–1722.
   PubMed Web of Science ®Google Scholar
• ZHAO Q, TEMSAMANI J, IADAROLA PL, JIANG Z, AGRAWAL S: Effect of different chemically modified oligodeoxynucleotides on immune stimulation. Bio-chem. Pharmacol. (1995) 51:173–182.
   Web of Science ®Google Scholar
• MONTEITH DK, HENRY SP, HOWARD RB et al: Immune stimulation - a class effect of phosphorothioate oli-godeoxynucleotides in rodents. Anticancer Drug Des. (1997) 12:421–32.
   PubMedGoogle Scholar
• INOUE H, HAYASE Y, IWAI S et al.: Sequence dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H. FEBS Lett. (1987) 215:327–330.
   PubMed Web of Science ®Google Scholar
• CHIANG M-Y, CHAN H, ZOUNES MA, FREIER SM, LIMAWF, BENNETT CF: Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J. Biol. Chem. (1991) 266:18162–18171.
   PubMed Web of Science ®Google Scholar
• SIERAKOWSKA H, SAMBADE MJ, AGRAWAL S et al: Re-pair of thalassemic human B-globin mRNA in mam-malian cells by antisense oligonucleotides. Proc. Natl. Acad. Sci. USA (1996) 93:12840–12844.
   PubMed Web of Science ®Google Scholar
• AZAD RF, DRIVER VB, TANAKA K, CROOKE RM, ANDER-SON KP: Antiviral activity of a phosphorothioate oligo-nucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Anti-microb. Agents Chem. (1993) 37:1945–1954.
   PubMed Web of Science ®Google Scholar
• ANDERSON KP., FOX MC, BROWN-DRIVER V et al.: Inhi-bition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide com-plementary to immediate-early RNA. Antimicrob. Agents Chemother. (1996) 40:2004–2011.
   Google Scholar
• BAKER BF, LOT SF, CONDON TP et al.:methoxy) ethyl modified anti-ICAM-1 oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation intiation complex in HUVECs. J. Biol. Chem. (1997) 272:11994–12000.
   PubMed Web of Science ®Google Scholar
• KILKUSKIE RE, FIELD AK: Antisense inhibition of virusinfections. Adv. Pharmacol. (1997) 40:437–483.
   PubMedGoogle Scholar
• GUINOT P, MARTIN R, BONVOISIN B et al: First Phase I study of a new systemic anti-CMV antisense compound (GEM(r) 132) in healthy male volunteers. 4th Confer-ence Retroviruses and Opportunistic Infections (1997):A742
   Google Scholar
• AGRAWAL S, TANG JY: GEM 91 An antisense oligonu-cleotide phosphorothioate as a therapeutic agent for AIDS. Antisense Res. Dev. (1992) 2:261–266.
   PubMedGoogle Scholar
• LISZIEWICZ J, SUN D, WEICHOLD FF et al.: Antisense oli-godeoxynucleotide phosphorothioate complemen-tary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells. Proc. Natl. Acad. Sci. USA (1994) 91:7942–7946.
   PubMed Web of Science ®Google Scholar
• AGRAWAL S, IKEUCHI T, SUN D et al.: Inhibition of hu-man immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynu-cleotides and their phosphorothioate analogues. Proc. Natl. Acad. Sci. USA (1989) 86:7790–7794.
   PubMed Web of Science ®Google Scholar
• LISZIEWICZ J, SUN D, METELEV V, ZAMECNIK P, GALLORC, AGRAWAL S: Long-term treatment of human immu-nodeficiency virus-infected cells with antisense oligo-nucleotide phosphorothioates. Proc. Natl. Acad. Sci. USA (1993) 90:3860–3864.
   PubMed Web of Science ®Google Scholar
• STEIN CA, TONKINSON JL, YAKUBOV L: Phos-phorothioate oligodeoxynucleotides - antisense in-hibitors of gene expression. Pharmacol Ther. (1991) 52:365–384.
   PubMed Web of Science ®Google Scholar
• STEIN CA, NECKERS M, NAIR BC, MUMBAUER S, HOKE G,PAL R: Phosphorothioate oligodeoxycytidine inter-feres with binding of 11IV-1 gp120 to CD4. J. Acquired Immune Deficiency Syndromes (1991) 4:686–693.
   PubMed Web of Science ®Google Scholar
• BAYEVER E, IVERSEN P: Oligonucleotides in the treat-ment of leukemia. Hematol. Oncol. (1994) 12:9–14.
   PubMed Web of Science ®Google Scholar
• REED JC, CUDDY M, HALDAR S et al: BCL2-mediated tu-morigenicity of a human T-lymphoid cell line: Syn-ergy with MYC and inhibition by BCL2 antisense. Proc. Natl. Acad. Sci. USA (1990) 87:3660–3664.
   PubMed Web of Science ®Google Scholar
• REED JC: Regulation of apoptosis by bc1-2 family pro-teins and its role in cancer and chemoresistance. Curr. Opin. Oncol (1995) 7:541–546.
   PubMed Web of Science ®Google Scholar
• COTTER FE, JOHNSON P, HALL P et al.: Antisense oligo-nucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene (1994) 9:3049–3055.
   PubMed Web of Science ®Google Scholar
• WESTIN EH, GALLO RC, ARYA SE et al: Differential ex-pression of the AMV gene in human hematopoietic cells. Proc. Natl. Acad. Sci. USA (1982) 79:2194–2199.
   PubMed Web of Science ®Google Scholar
• CALABRETTA B, SIMS RB, VALTIERI M et al.: Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oli-godeoxynucleotides: an in vitro study relevant to bone marrow purging. Proc. Natl. Acad. Sgt. USA (1991) 88:2351–2355.
   PubMed Web of Science ®Google Scholar
• ANFOSSI G, GEWIRTZ AM, CALABRETTA B:. An oligomer complementary to c-myb induced mRNA inhibits pro-liferation of myeloid leukemia cell lines. Proc. Natl. Acad. Sci. USA (1989) 86:3379–3384.
   Google Scholar
• RATAJCZAK MZ, KANT JA, LUGER SM et al: In vivo treat-ment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA (1992) 89:11823–11827.
   PubMed Web of Science ®Google Scholar
• GEWIRTZ AM: Developing oligonucleotide therapeu-tics for human leukemia. Anticancer Drug Des. (1997) 12:341–358.
   PubMedGoogle Scholar
• NISHIZUKA Y: Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Sci-ence (1992) 258:607–614.
   PubMed Web of Science ®Google Scholar
• ASAOKA Y, NAKAMURA S, YOSHIDA K, NISHIZUKA Y: Protein kinase C, calcium and phospholipid degrada-tion. Trends Biochem. ScL (1992) 17:414–417.
   PubMed Web of Science ®Google Scholar
• DEKKER LV, PARKER PJ: Protein kinase C-a F255 ques-tion of specificity. Trends Biochem. Sci. (1994)19:73–77.
   PubMed Web of Science ®Google Scholar
• YUSPA SH: The pathogenesis of squamous cell cancer: Lessons learned from studies of skin carcinogenesis, thirty-third G.H.A. Clowes memorial award lecture. Cancer Res. (1994) 54:1178–1189.
   PubMed Web of Science ®Google Scholar
• DEAN NM, MCKAY R, CONDON TP, BENNETT CF: Inhibi-tion of protein kinase C-a expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters../. Biol. Chem. (1994) 269:16416–16424.
   PubMed Web of Science ®Google Scholar
• DEAN NM, MCKAY R: Inhibition of protein kinase C-alpha expression in mice after systemic administra-tion of phosphorothioate antisense oligodeoxynu-cleotides. Proc. Natl. Acad. Sci. USA (1 9 9 4) 91:11762–11766.
   Google Scholar
• LIAO D-F, MONIA BP, DEAN N, BERK BC: Protein kinase zeta mediates angiotensin II activation of ERK 1/2 in vascular smooth muscle cells. J. Biol. Chem. (1997) 272:6146–6150.
   PubMed Web of Science ®Google Scholar
• LEVESQUE L, DEAN NM, SASMOR H, CROOKE ST: An-tisense oligonucleotides targeting human protein ki-nase C-a inhibit phorbol ester-induced reduction of bradykinin-evoked calcium mobilization in A549 cells. Mol. Pharmacol. (1996) 51:209–216.
   Web of Science ®Google Scholar
• LEE Y-S, DLUGOSZ AA, MCKAY R, DEAN NM, YUSPA SH: Specific antisense oligonucleotides define a role for PKC-a in expression of differentiation markers in nor-mal and neoplastic mouse epidermal keratinocytes. Molecular Carcinogenesis (1997) 18:1689–1696.
   Google Scholar
• LEVESQUE L, CROOKE ST: Depletion of PKC-a by an-tisense oligonucleotides alters B-adrenergic function and reverses the phorbol ester-induced reduction of isoproterenol-induced cAMP accumulation in murine Swiss 3T3 fibroblasts. J. Pharmacol. Exp. Ther. (1999) (In Press).
   Google Scholar
• YAZAKI T, AHMAD S, CHAHLAVI A et al.: Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-a phosphorothioate oli-godeoxynucleotide. Mol. Pharmacol (1996) 50:236–242.
   PubMed Web of Science ®Google Scholar
• SIKIC BI, YUEN AR, HALSEY J et al.: A Phase I trial of an antisense oligonucleotide targeted to protein kinase C-alpha (ISIS 3521) delivered by 21-day continous in-travenous infusion. Proc. Am. Soc. Clin. Oncol (1997) 16:212a.
   Google Scholar
• RAPP UR: Role of Raf-1 serine/threonine protein ki-nase in growth fator signal transduction. Oncogene. (1991) 6:495–600
   PubMed Web of Science ®Google Scholar
• WILLIAMS NG, ROBERTS TM, LIP: Both p21 ras and pp60 v-src are required, but neither alone is sufficient to activate the Raf-1 kinase. Proc. Natl. Acad. ScL USA (1992) 89:2922–2926.
   PubMed Web of Science ®Google Scholar
• HOWE LR., LEEVERS SJ, GOMEZ N, NAKIELNY S, COHEN P, MARSHALL CJ: Activation of the MAP kinase pathway by the protein kinase raf. Cell (1992) 71:335–342.
   PubMed Web of Science ®Google Scholar
• DAUM G, EISENMANN-TAPPE I, FRIES H-W, TROPPMAIR J, R. U. R. The ins and outs of Raf kinases. Trends Biol. ScL (1994) 19:279–283.
   PubMed Web of Science ®Google Scholar
• WANG HG, MIYASHITA T, TAKAYAMA S et al.: Apoptosis regulation by interaction of bc1-2 protein and Raf-1 ki-nase. Oncogene (1994) 9:2751–2756.
   PubMed Web of Science ®Google Scholar
• MONIA BP, JOHNSTON JF, GEIGER T, MULLER M, FABBRO D: Antitumor activity of a phosphorothioate oligode-oxynucleotide targeted against C-raf kinase. Nature Med. (1996) 2:668–675.
   PubMed Web of Science ®Google Scholar
• MONIA BP, SASMOR H, JOHNSTON JF et al.: Sequence-specific antitumor activity of a phosphorothioate oli-godeoxyribonucleotide targeted to human C-raf ki-nase supports an antisense mechanism of action in vivo. Proc. Natl. Acad. ScL USA (1996) 93:15481–15484.
   PubMed Web of Science ®Google Scholar
• CIOFFI CL, GARAY M, JOHNSON JF et al: Selective inhibi-tion of a-rafand c-rafmRNA expression by antisense oligodeoxynucleotides in rat vascular smooth muscle cells: Role of a-rafand c-rafin serum-induced prolif-eration. Mol Pharmacol. (1997) 51:383–389.
   PubMed Web of Science ®Google Scholar
• SCHULTE TW V, BLAGOSKLONNY M, ROMANOVA L et al: Destabilization of raf-1 by geldanamycin leads to dis-ruption of the raf-l-MEK-mitogen-activated protein ki-nase signalling pathway. Mol. Cell Biol. (1996) 16:5839–5845.
   PubMed Web of Science ®Google Scholar
• MONIA BP: Disruption of the MAP kinase signalling pathway using antisense oligonucleotide inhibitors targetd to ras and raf kinase. In: Applied Antisense Oligo-nucleotide Technology. Stein C, Krieg A (Eds.), John Wiley and Sons, London, UK (1998) :245–261.
   Google Scholar
• CHANG EH, FURTH ME, SCOLNICK EM, LOWY DR: Tumo-rigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus. Nature (1982) 297:479–483.
   PubMed Web of Science ®Google Scholar
• LOHMANN SM, WALTER U: Regulation of the cellular and subcellular concentrations and distribution of cy-clic nucleotide-dependent protein kinases. In: Ad-vances in Cyclic Nucleotide and Protein Phosphoiylation Research. Greengard P, Robison GA (Eds.), Raven, New York, USA (1984):63–117.
   Google Scholar
• CHO-CHUNG YS: Perspectives in cancer research: Role of cyclic AMP receptor proteins in growth, differentia-tion, and suppression of malignancy: new approaches to therapy. Cancer Res. (1990) 43:2736–2740.
   Google Scholar
• TORTORA G, YOKOZAKI H, PEPE S et al.: Differentia-tion of HL-60 leukemia by type I regulatory subunit an-tisense oligodeoxynucleotide of cAMP-dependent protein kinase. Proc. Natl. Acad. Sci. USA (1991) 88:2011–2015.
   PubMed Web of Science ®Google Scholar
• NESTEROVA M, CHO-CHUNG YS: A single-injection pro-tein kinase A-directed antisense treatment to inhibit tumor growth. Nature Med. (1995) 1:528–533.
   PubMed Web of Science ®Google Scholar
• YOKOZAKI H, BUDILLON A, TORTORA G et al: An an-tisense oligodeoxynucleotide that depletes RIa subunit of cyclic AMP-dependent protein kinase in-duces growth inhibition in human cancer cells. Cancer Res. (1993) 53:868–872.
   PubMed Web of Science ®Google Scholar
• CHO-CHUNG YS: Protein kinase A-directed antisense blockade of cancer growth: single gene-based thera-peutic approach. In: Applied Antisense Oligonucleotide Technology Stein CA, Krieg AM (Eds.), Wiley-Liss, New York, USA (1998):263–281.
   Google Scholar
• DUSTIN ML, SPRINGER TA: Role of lymphocyte adhe-sion receptors in transient interactions and cell loco-motion. Annu. Rev. Immunol. 9:27–66.
   Google Scholar
• SPRINGER TA: Adhesion receptors of the immune sys-tem. Nature (1990) 346:425–434.
   PubMed Web of Science ®Google Scholar
• BUTCHER EC: Leukocyte-endothelial cell recognition: Three (or more) steps to specificity and diversity. Cell (1991) 67:1033–1036.
   PubMed Web of Science ®Google Scholar
• BENNETT CF, CONDON T, GRIMM S, CHAN H, CHIANG M-Y: Inhibition of endothelial cell-leukocyte adhesion molecule expression with antisense oligonucleotides. Immunol (1994) 152:3530–3540.
   Web of Science ®Google Scholar
• MIELE ME, BENNETT CF, MILLER BE, WELCH DR: En-hanced metastatic ability of TNF-a-treated malignant melanoma cells is reduced by intercellular adhesion molecule-1 (ICAM- 1, CD54) antisense oligonucleo-tides. Exp. Cell Res. (1994) 214:231–241.
   PubMed Web of Science ®Google Scholar
• NESTLE FO, MITRA RS, BENNETT CF, CHAN H, NICK-OLOFF BJ: Cationic lipid is not required for uptake and selective inhibitory activity of ICAM-1 phos-phorothioate antisense oligonucleotides in keratino-cytes. J. Invest. Dermatol. (1994) 103:569–575.
   PubMed Web of Science ®Google Scholar
• CHRISTOFIDOU-SOLOMIDOU M, ALBELDA SM, BENNETT FC, MURPHY GF: Experimental production and modu-lation of human cytotoxic dermatitis in human-murine chimeras. Am. J. Pathol (1997) 150:631–639.
   PubMed Web of Science ®Google Scholar
• STEPKOWSKI SM, TU Y, CONDON TP, BENNETT CF: Blocking of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities. J. Immunol. (1994) 153:5336–5346.
   PubMed Web of Science ®Google Scholar
• KATZ SM, BROWNE B, PHAM T et al: Efficacy of ICAM-1 antisense oligonucleotide in pancreatic islet transpla-nation. Transplant. Proc. (1995) 27:3214.
   PubMed Web of Science ®Google Scholar
• KUMASAKA T, QUINLAN WM, DOYLE NA et al.: The role of the intercellular adhesion molecule-1 (ICAM-1) in endotoxin-induced pneumonia evaluated using ICAM-1 antisense oligonucleotides, anti-ICAM-1 monoclonal antibodies, and ICAM-1 mutant mice. J. Clin. Invest. (1996) 97:2362–2369.
   PubMed Web of Science ®Google Scholar
• HALLER H, DRAGUN D, MIETHKE A et al.: Antisense oli-gonucleotides for ICAM-1 attenuate reperfusion injury and renal failure in the rat. Kidney Int. (1996) 50:473–480.
   PubMed Web of Science ®Google Scholar
• YACYSHYN B, WOLOSCHUK B, YACYSHYN MB et al.: Effi-cacy and safety of ISIS 2302 (ICAM-1 antisense oligonu-cleotide) treatment of steroid-dependnet Crohn's disease. Gastroenterology (1997) 112:A1123.
   Web of Science ®Google Scholar
• KAWASAKI AM, CASPER MD, FREIER SM et al.: Uniformly modified 2'-deoxy-2'-fluoro phosphorothioate oligo-nucleotides as nuclease-resistant antisense com-pounds with high affinity and specificity for RNA targets. J. Med. Chem. (1993) 36:831–841.
   PubMed Web of Science ®Google Scholar
• WAGNER RW, MATTEUCCI MD, LEWIS JG, GUTIERREZ AJ, MOULDS C, FROEHLER BC: Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimid-ines. Science (1993) 260:1510–1513.
   PubMed Web of Science ®Google Scholar
• NIELSEN PE, EGHOLM M, BERG RH, BUCHARDT 0: Sequence-selective recognition of DNA by strand dis-placement with a thymine-substituted polyamide. Sci-ence (1991) 254:1497–1500.
   PubMed Web of Science ®Google Scholar
• BENNETT CF, ZUCKERMAN JE, KORNBRUST D, SASMOR H, LEEDS JM, CROOKE ST: Pharmacokinetics in mice of a [311]-labeled phosphorothioate oligonucleotide for-mulated in the presense and absence of a cationic lipid. J. Control. Rel. (1996) 41:121–130.
   Web of Science ®Google Scholar
• ZHANG R, IYER RP, YU D et al.: Pharmacokinetics and tissue distribution of a chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous admini-stration. J. Pharmacol. Exp. Ther. (1996) 278:971–979.
   PubMed Web of Science ®Google Scholar
• HENRY SP, ZUCKERMAN JE, ROJKO J et al.: Toxicologic properties of several novel oligonucleotide analogs in mice. Anticancer Drug Des. (1996) 12:1-14. C Frank Bennett ISIS Pharmaceuticals, 2280 Faraday Ave., Carlsbad, CA 92008, USA Tel.: +1 760 603 2336; Email: [email protected]
   Google Scholar